<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02716012</url>
  </required_header>
  <id_info>
    <org_study_id>MNA-3521-011</org_study_id>
    <secondary_id>2015-003051-21</secondary_id>
    <secondary_id>20332</secondary_id>
    <nct_id>NCT02716012</nct_id>
  </id_info>
  <brief_title>First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer</brief_title>
  <acronym>OUTREACH</acronym>
  <official_title>A First-in-Human, Multi-centre, Open-label, Phase 1a/b Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA to Investigate Its Safety, Tolerability, and Antitumour Activity in Patients With Advanced Liver Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mina Alpha Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mina Alpha Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MNA-3521-011 study is a multi-centre, open-label, first-in-human, phase 1a/b clinical study&#xD;
      dose/dose frequency escalation followed by a cohort expansion part. MTL-CEBPA is administered&#xD;
      as monotherapy or in combination with sorafenib to patients with advanced hepatocellular&#xD;
      carcinoma and cirrhosis of the liver. All participants will be considered unsuitable for&#xD;
      liver tumour resection and/or is refractory to radiotherapy and other loco-regional&#xD;
      therapies.&#xD;
&#xD;
      MTL-CEBPA consists of a double stranded RNA formulated into a SMARTICLES® liposomal&#xD;
      nanoparticle and is designed to activate the CEBPA gene.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1- Incidence of Grade 3 or 4 drug related adverse events</measure>
    <time_frame>During cycle 1 (28 days) of treatment assessed over 15 months</time_frame>
    <description>Frequency of adverse events graded according to NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 - Change in tumour size from baseline using RECIST 1.1 and mRECIST in patients treated with MTL-CEBPA in combination with sorafenib</measure>
    <time_frame>Eight weekly intervals until death assessed for 100 weeks</time_frame>
    <description>Increase or decrease in tumour measurement using Response Evaluation Criteria in Solid Tumours (RECIST) reports</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2 - Safety and tolerability of co-administering MTL-CEBPA with sorafenib assessed using frequency of adverse events graded according to toxicity criteria (NCI CTCAE v 5.0) and categorised by body system</measure>
    <time_frame>At the end of every cycle (28 days) of treatment assessed over 15 months</time_frame>
    <description>Frequency of treatment-related adverse events graded according to NCI CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>MTL-CEBPA Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTL-CEBPA administered weekly, twice weekly or thrice weekly over 3 weeks followed by 1 week of rest defining a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTL-CEBPA &amp; Sorafenib (combination)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTL-CEBPA is administered weekly or twice weekly in combination with sorafenib over 3 weeks followed by 1 week of rest defining a 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTL-CEBPA &amp; Sorafenib (sequential)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTL-CEBPA is administered weekly or twice weekly for 2 cycles (28-day cycle) followed by 2 cycles of sorafenib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTL-CEBPA</intervention_name>
    <description>Intravenous administration</description>
    <arm_group_label>MTL-CEBPA &amp; Sorafenib (combination)</arm_group_label>
    <arm_group_label>MTL-CEBPA &amp; Sorafenib (sequential)</arm_group_label>
    <arm_group_label>MTL-CEBPA Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib 200mg</intervention_name>
    <description>Sorafenib tablets</description>
    <arm_group_label>MTL-CEBPA &amp; Sorafenib (combination)</arm_group_label>
    <arm_group_label>MTL-CEBPA &amp; Sorafenib (sequential)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed advanced HCC with cirrhosis resulting from hepatitis B,&#xD;
             hepatitis C, alcohol-related liver disease or any other aetiology OR Histologically&#xD;
             confirmed advanced HCC resulting from NASH with or without cirrhosis&#xD;
&#xD;
          -  Patient is considered unsuitable for liver tumour resection and/or is refractory to&#xD;
             radiotherapy and other loco-regional therapies&#xD;
&#xD;
          -  At least one measurable lesion with target lesion size ≥ 1.0 cm as measured by MRI or&#xD;
             CT&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Child-Pugh class A or B (up to B7)&#xD;
&#xD;
          -  Eligible to undergo pre and post treatment mandated biopsies&#xD;
&#xD;
          -  Acceptable laboratory parameters, as demonstrated by:&#xD;
&#xD;
               -  Platelets ≥ 70 x 10^9/L&#xD;
&#xD;
               -  Serum albumin &gt; 26 g/L&#xD;
&#xD;
               -  ALT and AST ≤ 5 x ULN&#xD;
&#xD;
               -  Bilirubin ≤ 50 µmol /L&#xD;
&#xD;
               -  WBC ≥ 2.0 x 10^9/L, Absolute neutrophil count ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Haemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  Prothrombin time (PT) &lt;20 seconds&#xD;
&#xD;
          -  Acceptable renal function as demonstrated by:&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
               -  Calculated creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have been treated with TACE or chemotherapy within the last 28 days&#xD;
&#xD;
          -  Prior investigational drugs within the last 30 days&#xD;
&#xD;
          -  Grade &gt; 1 prior treatment-related toxicities (excluding alopecia) at the time of&#xD;
             screening&#xD;
&#xD;
          -  Patients with clinically significant cancer ascites&#xD;
&#xD;
          -  Any episode of bleeding from oesophageal varices or other uncontrolled bleeding within&#xD;
             the last 3 months prior to study treatment initiation&#xD;
&#xD;
          -  Patients with history of haemorrhage or gastrointestinal perforation&#xD;
&#xD;
          -  Patients administered with serum albumin within the last 7 days prior to the first&#xD;
             study drug administration&#xD;
&#xD;
          -  Known infection with human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Patients with central nervous system (CNS), bone or peritoneal metastasis&#xD;
&#xD;
          -  Patients presenting with marked baseline prolongation of QT/QTc interval defined as&#xD;
             repeated demonstration of a QTc interval ≥450 ms (males) and ≥460 ms (females) using&#xD;
             Fridericia's correction formula&#xD;
&#xD;
          -  Signs and symptoms of heart failure characterised as greater than the New York Heart&#xD;
             Association (NYHA) Class I or other clinically significant cardiac abnormalities&#xD;
             (including history of myocardial infarction) including stable abnormalities.&#xD;
&#xD;
          -  Major surgery within the last 30 days prior to study treatment initiation&#xD;
&#xD;
          -  Patients with history of organ transplantation or cardiac surgery&#xD;
&#xD;
          -  Patients with sepsis, ineffective biliary drainage with or without cholangitis,&#xD;
             obstructive jaundice or encephalopathy at screening visit or within the last two weeks&#xD;
             prior to study treatment initiation, whichever earlier&#xD;
&#xD;
          -  Evidence of spontaneous bacterial peritonitis or renal failure or allergic reactions&#xD;
             to the agent or excipient at screening visit or within the last two weeks prior to&#xD;
             study treatment initiation, whichever earlier&#xD;
&#xD;
          -  Known hypersensitivity to the active sorafenib or to any of the excipients&#xD;
&#xD;
          -  Occurrence of a grade 3 or higher sorafenib or lenvatinib related toxicity during any&#xD;
             sorafenib / lenvatinib treatment received prior to study enrolment, according to&#xD;
             toxicity criteria (NCI CTCAE v 5.0)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Debashis Sarker, MBChB, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust and King's College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Professor Nagy Habib, FRCS</last_name>
    <role>Study Director</role>
    <affiliation>Mina Alpha Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St. Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://minatx.com</url>
    <description>Company Webpage</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oligonucleotide</keyword>
  <keyword>RNA</keyword>
  <keyword>saRNA</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Myeloid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

